Literature DB >> 35645622

Novel Heterozygous Variants in the HLA-DRB1 Gene in a Saudi Family With Early-Onset Familial Multiple Sclerosis: Therapeutic Failure and Success.

Hussein Algahtani1, Bader Shirah2, Randa Khafaji3, Sarah Algahtani4.   

Abstract

Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system. Familial MS is arbitrarily defined as a type of MS that runs in families with 1 or more first- to third-degree relatives in addition to the index case affected by MS. The aim of this article is to report a unique case of familial MS from Saudi Arabia with 2 novel variants in the HLA-DRB1 gene that may contribute to the pathogenesis. We observed an unfavorable response to interferon therapy and successful treatment using fingolimod therapy. This observation needs further study, including whether this lack of response is specific to interferon treatment or possibly a chance occurrence. This family work-up illustrates the importance of genetic testing in identifying variants associated with familial MS, especially if more than 2 members of the same family are affected. Although this genetic tool is used mainly for research purposes, it had clinical implications for our patient, including the appropriate selection of disease-modifying therapy and prognostic counseling. Further large-scale studies are needed to expand the genetic spectrum of familial MS with clinical and pharmacologic correlation.
© 2022 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Familial MS; Fingolimod; Genetic testing; HLA-DRB1; Interferon

Year:  2021        PMID: 35645622      PMCID: PMC9135370          DOI: 10.7224/1537-2073.2020-125

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  18 in total

Review 1.  Multiple sclerosis genetics.

Authors:  Stephen Sawcer; Robin J M Franklin; Maria Ban
Journal:  Lancet Neurol       Date:  2014-05-19       Impact factor: 44.182

2.  Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.

Authors:  F Montarolo; S Perga; S Martire; F Brescia; M Caldano; M Lo Re; G Panzica; A Bertolotto
Journal:  Eur J Neurol       Date:  2018-12-22       Impact factor: 6.089

3.  Clinical and diagnostic features of patients with familial multiple sclerosis.

Authors:  Denas Andrijauskis; Renata Balnyte; Ieva Keturkaite; Antanas Vaitkus
Journal:  Med Hypotheses       Date:  2019-07-13       Impact factor: 1.538

4.  Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.

Authors:  Hussein Algahtani; Bader Shirah; Yaser Al Malik; Ibraheem Meftah
Journal:  Clin Neuropharmacol       Date:  2020 Mar/Apr       Impact factor: 1.592

Review 5.  Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis.

Authors:  Mohammad Hossein Harirchian; Farzad Fatehi; Payam Sarraf; Niyaz Mohammadzadeh Honarvar; Sama Bitarafan
Journal:  Mult Scler Relat Disord       Date:  2017-12-24       Impact factor: 4.339

Review 6.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

7.  Familial multiple sclerosis: does consanguinity have a role?

Authors:  M Al Jumah; S Kojan; A Al Khathaami; I Al Abdulkaream; M Al Blawi; A Jawhary
Journal:  Mult Scler       Date:  2010-12-21       Impact factor: 6.312

Review 8.  Genetics of Multiple Sclerosis: An Overview and New Directions.

Authors:  Nikolaos A Patsopoulos
Journal:  Cold Spring Harb Perspect Med       Date:  2018-07-02       Impact factor: 6.915

9.  The association of HLA-DRB1 and HLA-DQB1 alleles with genetic susceptibility to multiple sclerosis in the Slovak population.

Authors:  Jozef Michalik; Daniel Čierny; Ema Kantorová; Daniela Kantárová; Javor Juraj; Zuzana Párnická; Egon Kurča; Dušan Dobrota; Ján Lehotský
Journal:  Neurol Res       Date:  2016-01-08       Impact factor: 2.448

10.  Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.

Authors:  Mohammed AlJumah; R Bunyan; H Al Otaibi; G Al Towaijri; A Karim; Y Al Malik; M Kalakatawi; S Alrajeh; M Al Mejally; H Algahtani; A Almubarak; E Cupler; S Alawi; S Qureshi; S Nahrir; A Almalki; A Alhazzani; I Althubaiti; N Alzahrani; E Mohamednour; J Saeedi; S Ishak; H Almudaiheem; A El-Metwally; A Al-Jedai
Journal:  BMC Neurol       Date:  2020-02-08       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.